title: Utilizing the BiTE (bispecific T-cell engager) platform for immunotherapy of cancer.
abstract: Various approaches of T-cell-based cancer immunotherapy are currently under investigation, among these are BiTE® (bispecific T-cell engager) antibody constructs, which have a unique design and mechanism of action. They are constructed by genetically linking onto a single polypeptide chain the minimal binding domains of monoclonal antibodies for tumor-associated surface antigens and for the T-cell receptor-associated molecule CD3. Concurrent engagement of the target cell antigen and CD3 leads to activation of polyclonal cytotoxic T-cells, resulting in target cell lysis. Blinatumomab, a BiTE targeting CD19, is being investigated in a broad range of B-cell malignancies and has recently been approved in the USA by the US FDA for Philadelphia chromosome-negative relapsed/refractory B-acute lymphoblastic leukemia under the trade name BLINCYTO™. The BiTE platform is one of the clinically most advanced T-cell immunotherapy options.
authors.affiliation: Amgen Research (Munich), Global Clinical Development, Therapeutic Area Oncology , Staffelseestraße 2, Munich 81477 , Germany.
authors.forename: Julia
authors.initials: J
authors.lastname: Stieglmaier
authors.forename: Jonathan
authors.initials: J
authors.lastname: Benjamin
authors.forename: Dirk
authors.initials: D
authors.lastname: Nagorsen
mesh_terms: D018033:Antibodies, Bispecific / Q000276:immunology / Q000494:pharmacology / Q000627:therapeutic use*; D018941:Antigens, CD19 / Q000276:immunology / Q000378:metabolism; D000951:Antigens, Neoplasm / Q000276:immunology; D000970:Antineoplastic Agents / Q000276:immunology / Q000494:pharmacology / Q000627:therapeutic use; D001402:B-Lymphocytes / Q000276:immunology; D017252:CD3 Complex / Q000276:immunology; D002986:Clinical Trials as Topic / Q000379:methods; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D009369:Neoplasms / Q000188:drug therapy / Q000276:immunology; D011948:Receptors, Antigen, T-Cell / Q000276:immunology; D013602:T-Lymphocytes, Cytotoxic / Q000187:drug effects / Q000276:immunology
chemical_list: D018033:Antibodies, Bispecific; D018941:Antigens, CD19; D000951:Antigens, Neoplasm; D000970:Antineoplastic Agents; D017252:CD3 Complex; D011948:Receptors, Antigen, T-Cell; C510808:blinatumomab
keywords: BiTE®; T-cells; bispecific antibody; blinatumomab; cancer immunotherapy